Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Clinical trial Stories

2014-04-09 16:23:19

LONDON, April 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Thyroid Cancer Global Clinical Trials Review, H2, 2013Thyroid Cancer Global Clinical Trials Review, H2, 2013SummaryGlobalData's clinical trial report, "Thyroid Cancer Global Clinical Trials Review, H2, 2013" provides data on the Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thyroid Cancer. It includes an overview...

2014-04-08 23:21:41

Comprehensive cloud-based Clinical Trial Optimization System transforms clinical operations quality and efficiency from startup through closeout with a single unified platform. Newton, MA (PRWEB) April 08, 2014 TrialNetworks and its Clinical Trial Optimization System won the Disruptive Innovator and Technology of the Year award from Partnerships in Clinical Trials 2014. The award was announced on the final day of the premier industry conference held in Las Vegas, NV. The award honors an...

2014-04-08 13:04:46

Trial identifies breast cancer patients likely to benefit from experimental drug In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer. Additionally, researchers learned that an algorithm used in the adaptive, randomized trial known as I-SPY 2 was highly effective at predicting the success of the treatment regimen in the...

2014-04-08 12:25:55

LONDON, April 8, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Diabetic Macular Edema Global Clinical Trials Review, H2, 2013Diabetic Macular Edema Global Clinical Trials Review, H2, 2013SummaryGlobalData's clinical trial report, "Diabetic Macular Edema Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Macular Edema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic...

2014-04-07 12:34:11

LONDON, April 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Ventricular Arrhythmia Global Clinical Trials Review, H2, 2013 Ventricular Arrhythmia Global Clinical Trials Review, H2, 2013 SummaryGlobalData's clinical trial report, "Ventricular Arrhythmia Global Clinical Trials Review, H2, 2013" provides data on the Ventricular Arrhythmia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on...

2014-04-07 08:31:14

BRIDGEWATER, N.J., April 7, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the appointment of three new board members. "We are very pleased to welcome Cora M. Tellez, Taunia S. Markvicka, and Michael W. George to the CorMedix team. The addition of these highly accomplished industry veterans represents...

2014-04-07 08:31:07

Company Corrects His False Claims About Annual Report and Phase III Trial BETHESDA, Md., April 7, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today again set the record straight: Adam Feuerstein's latest, sensationalized headline claims about the Company's annual report and Phase III trial are once again factually wrong and materially misleading....

2014-04-07 08:29:21

TORONTO, April 7, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) provided an update on the development of its drug candidates and plans for future growth. The addition of the neuropsychiatric drug candidate ELND005 has broadened the Company's development pipeline with an un-partnered late-stage clinical asset, coupled with Transition's core strategy of advancing assets acquired from pharmaceutical partners. From a...

2014-04-04 23:34:34

Innovative Adaptive Designs Increase Trial Flexibility and Efficiency, Generating Significant Ethical and Economic Advantages Reston, Virginia (PRWEB) April 03, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development, will present emerging strategies for using adaptive trial designs to improve the success...

2014-04-04 23:33:41

MPI’s Drug Response Predictor (DRP) can generate new and unique clinically relevant gene signatures - a strong complementary drug development tool; TD2 is an oncology drug development company that customizes clinical trial design and execution for its customers by applying rigorous and high-throughput translational preclinical development, with best in class regulatory and clinical expertise. Scottsdale, Ariz., USA and Hoersholm, Denmark (PRWEB) April 03, 2014 Medical Prognosis...